- Home
- WSBF vs LRMR Comparison
WSBF vs LRMR Comparison
Compare WSBF & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- LRMR
- Stock Information
- Founded
- WSBF 1921
- LRMR N/A
- Country
- WSBF United States
- LRMR United States
- Employees
- WSBF N/A
- LRMR N/A
- Industry
- WSBF Savings Institutions
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- WSBF Finance
- LRMR Health Care
- Exchange
- WSBF Nasdaq
- LRMR Nasdaq
- Market Cap
- WSBF 275.9M
- LRMR 309.8M
- IPO Year
- WSBF N/A
- LRMR N/A
- Fundamental
- Price
- WSBF $15.21
- LRMR $3.96
- Analyst Decision
- WSBF
- LRMR Strong Buy
- Analyst Count
- WSBF 0
- LRMR 8
- Target Price
- WSBF N/A
- LRMR $17.88
- AVG Volume (30 Days)
- WSBF 46.3K
- LRMR 1.3M
- Earning Date
- WSBF 10-21-2025
- LRMR 10-29-2025
- Dividend Yield
- WSBF 3.93%
- LRMR N/A
- EPS Growth
- WSBF 82.58
- LRMR N/A
- EPS
- WSBF 1.13
- LRMR N/A
- Revenue
- WSBF $134,196,000.00
- LRMR N/A
- Revenue This Year
- WSBF N/A
- LRMR N/A
- Revenue Next Year
- WSBF N/A
- LRMR N/A
- P/E Ratio
- WSBF $13.02
- LRMR N/A
- Revenue Growth
- WSBF 1.23
- LRMR N/A
- 52 Week Low
- WSBF $11.61
- LRMR $1.61
- 52 Week High
- WSBF $16.86
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- WSBF 68.83
- LRMR 54.10
- Support Level
- WSBF $14.65
- LRMR $3.78
- Resistance Level
- WSBF $14.85
- LRMR $4.26
- Average True Range (ATR)
- WSBF 0.29
- LRMR 0.27
- MACD
- WSBF -0.00
- LRMR -0.00
- Stochastic Oscillator
- WSBF 90.70
- LRMR 55.14
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the Community Banking segment.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.